Patents Examined by Brenda Coleman
  • Compositions and methods for treatment of cancer
    Patent number: 9447088
    Abstract: The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds in combination with chemotherapeutic agents. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention and also administering a effective amount of a chemotherapeutic agent.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: September 20, 2016
    Assignee: ArQule, Inc.
    Inventors: Chiang J. Li, Mark A. Ashwell, Jason Hill, Magdi Moussa, Neru Munshi
  • Compounds
    Patent number: 9447074
    Abstract: A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory diseases and/or allergic conditions, in cancer therapy, specifically heme malignancies, and autoimmune conditions.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: September 20, 2016
    Assignee: Glaxo Group Limited
    Inventors: Francis Louis Atkinson, Michael David Barker, John Liddle, David Matthew Wilson
  • Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
    Patent number: 9440948
    Abstract: Embodiments of the present disclosure provide for compounds such as those shown in FIG. 1.1 (compounds A, B, C, and D), 2?substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG. 1.2, compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2?substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: September 13, 2016
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: William Reade Kem, Ferenc Soti, Anne Rouchaud, Hong Xing, Jon Lindstrom, Kristin Marie Andrud
  • Compounds and compositions for modulating EGFR Activity
    Patent number: 9440957
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: September 13, 2016
    Assignee: Novartis AG
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya, Songchun Jiang
  • L-setastine hydrochloride and preparation method thereof
    Patent number: 9434705
    Abstract: The present invention relates to the field of medicine, and disclosed are an L-setastine hydrochloride and a preparation method therefor. The compound of the present invention has the advantages of stronger histamine Hi receptor antagonism and small side effect; the yield of the preparation method is more than 80%, and the product purity is high. The present invention also provides an application of the compound as an H1 histamine receptor antagonist.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: September 6, 2016
    Assignee: ANHUI QINGYUN PHARMACEUTICAL & CHEMICAL CO., LTD.
    Inventors: Qingyun Huang, Qingguo Huang, Meixian Lou
  • Process for the preparation of a benzazepine derivative
    Patent number: 9428461
    Abstract: Provided is an industrially scalable process for the preparation of a benzazepine derivative, namely, 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl benzoyl amino) benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (generically referred as Tolvaptan).
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: August 30, 2016
    Assignee: RPG LIFE SCIENCES LIMITED
    Inventors: Uday Rajaram Bapat, Ranjan Prasad Srivastava, Pravin Chaburao Kolhe, Pravin Ganpat Talekar
  • Acylated derivative of homoharringtonine, preparation method therefor, and application thereof
    Patent number: 9428519
    Abstract: The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and relates to novel homoharringtonine acylated derivatives of formula (I) and formula (II) and a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: August 30, 2016
    Assignee: HANGZHOU BENSHENG PHARMACEUTICAL CO., LTD.
    Inventors: Rongzhen Xu, Frank Rong, Fuwen Xie, Hongxi Lai
  • Dye, photoelectric conversion element using the same, photoelectrochemical cell, and method of producing dye
    Patent number: 9424998
    Abstract: A dye, having a structure represented by formula (1A): wherein A represents a group of atoms necessary for forming a ring together with the carbon-nitrogen bond; at least one of Y1A and Y2A represents an acidic group, in which when they each represent an acidic group, they may be the same as or different from each other, or when only one of them represents an acidic group, the other represents an electron-withdrawing group; D represents a group to give a dye; n represents an integer of 1 or greater; L represents a single bond or a divalent linking group; and Y3A represents an acidic group.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 23, 2016
    Assignee: FUJIFILM Corporation
    Inventors: Katsumi Kobayashi, Keizo Kimura, Tatsuya Susuki, Hirotaka Satou, Yukio Tani
  • Bromodomain inhibitors and uses thereof
    Patent number: 9422292
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: August 23, 2016
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Victor S. Gehling, Michael Charles Hewitt, Alexander M. Taylor, Jean-Christophe Harmange
  • Tetrahydro-pyrimidoazepines as modulators of TRPV1
    Patent number: 9422293
    Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: August 23, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
  • Polymorphic forms of alcaftadine
    Patent number: 9409913
    Abstract: The present invention relates to novel polymorphic forms of alcaftadine, processes of preparing novel polymorphic forms of alcaftadine and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: August 9, 2016
    Assignee: ENALTEC LABS PRIVATE LIMITED
    Inventors: Sivakumar Bobba Venkata, Eswara Rao Kodali, Girish Bansilal Patel, Sanjay Dashrath Vaidya, Alok Pramod Tripathi
  • Methods and compositions for preparing noribogaine from voacangine
    Patent number: 9403817
    Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: August 2, 2016
    Assignee: DEMERX, INC.
    Inventors: Deborah C. Mash, Robert M. Moriarty, Richard D. Gless, Jr.
  • Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
    Patent number: 9403776
    Abstract: The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R1-R9 are as defined herein.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: August 2, 2016
    Assignee: Albany Molecular Research, Inc.
    Inventors: Bruce F. Molino, Shuang Liu, Aruna Sambandam, Peter R. Guzzo, Min Hu, Congxiang Zha, Kassoum Nacro, David D. Manning, Matthew L. Isherwood, Kristen N. Ryan, Wenge Cui, Richard E. Olson
  • Stereoselective total synthesis of noribogaine
    Patent number: 9403837
    Abstract: This invention relates generally to methods for synthesizing the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: August 2, 2016
    Assignee: DEMERX, INC.
    Inventors: Robert M. Moriarty, Deborah C. Mash
  • Pyrazoline dione derivatives as NADPH oxidase inhibitors
    Patent number: 9394306
    Abstract: The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: July 19, 2016
    Assignee: GENKYOTEX SA
    Inventors: Patrick Page, Francesca Gaggini, Benoît Laleu
  • Process for the preparation of drospirenone
    Patent number: 9394334
    Abstract: It is described of a process for the preparation of drospirenone, the compound of formula 1 shown below, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions having contraceptive action, starting from 17?-(3-hydroxypropyl)-6?,7?;15?,16?-dimethylene-5?-androstane-3?,5,17?-triol.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: July 19, 2016
    Assignee: INDUSTRIALE CHIMICA S.R.L.
    Inventors: Roberto Lenna, Andrea Vanossi
  • Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
    Patent number: 9394295
    Abstract: The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: July 19, 2016
    Assignee: Janssen Sciences Ireland UC
    Inventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Anil Koul, Wendy Mia Albert Balemans
  • Antitumor aza-benzo [f] azulen derivative, method for preparing same, and use thereof
    Patent number: 9382249
    Abstract: The present invention relates to the field of pharmaceutical chemistry, and particularly to an aza-benzo[f]azulen derivative (I) and an antitumor effect thereof. Pharmacological tests show that the compound of the present invention has in vitro and in vivo antitumor activities, and can be developed into clinical drugs for treating or controlling diseases such as stomach cancer, lung cancer, liver cancer, breast cancer, colon cancer, prostate cancer, and oral cancer.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: July 5, 2016
    Assignee: TIANYI BIOSCIENCE CO., LTD.
    Inventors: Xihan Wu, Liwu Fu, Dongmei Zhang, Yurong Wang
  • Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
    Patent number: 9376396
    Abstract: The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 28, 2016
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Andreas Haupt, Jürgen Dinges, Liliane Unger, Karsten Wicke, Robert van Waterschoot, Scott Mittelstadt, Karla Drescher, Ana Relo
  • Tricyclic compounds for inhibiting the CFTR channel
    Patent number: 9359381
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 7, 2016
    Assignee: Novartis AG
    Inventors: Mahbub Ahmed, Alexander Ashall-Kelly, Louisa Gueritz, Jeffrey McKenna, Joseph McKenna, Simon Mutton, Rakesh Parmar, Jon Shepherd, Paul Wright